Contracts › 75N93022C00061
75N93022C00061: A Novel Lpxc Inhibitor With Pan-Resistant Pseudomonas and Burkholderia Activity.
Awarded to Revagenix Inc by National Institutes of Health (NIH).
$28.2Mobligated
$28.2Mpotential value
25 April 2028current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N93022C00061 |
|---|---|
| Awardee | Revagenix Inc |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | CA |
| Offers received | 30 |
| Period of performance | 22 September 2022 to 25 April 2028 |
| Potential end | 25 April 2028 |
| Estimated recompete solicitation | ~Q4 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record